ロード中...

A43 LONG-TERM EFFICACY AND SAFETY OF OBETICHOCLIC ACID IN PRIMARY BILIARY CHOLANGITIS: RESPONDER ANALYSIS OF OVER 5 YEARS OF TREATMENT IN THE POISE TRIAL

BACKGROUND: Obeticholic acid (OCA), a potent farnesoid X receptor agonist, is approved as second-line treatment for primary biliary cholangitis (PBC) in patients with an incomplete response or intolerance to ursodeoxycholic acid. AIMS: We evaluated the effect of OCA in PBC patients enrolled in the P...

詳細記述

保存先:
書誌詳細
出版年:J Can Assoc Gastroenterol
主要な著者: Hirschfield, G, Jones, D, Carbone, M, Bowlus, C L, Nevens, F, Kremer, A E, Liberman, A, MacConell, L, Hansen, B E
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958753/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwab002.041
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!